| Name | Lamar Estates, Llc |
|---|---|
| Location | 205 South 10th Street, Lamar, Colorado |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 60 |
| Occupancy Rate | 36% |
| Medicare ID (CCN) | 065294 |
| Legal Business Name | Lamar Estates, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1215935424 |
| Organization Name | JUNIPER HAVEN, LP |
| Doing Business As | JUNIPER VILLAGE AT LAMAR |
| Address | 205 S 10th St, Lamar, CO 81052 |
| Phone Number | 719-336-3434 |
News Archive
Researchers have developed cancer drug-packed 'grenades' armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
The World Health Organization (WHO), in consultation with the government of the United Kingdom, has designated the Liverpool School of Tropical Medicine (LSTM) as a WHO Collaborating Centre for Evidence Synthesis for Infectious and Tropical Diseases.
Galectin-3, a protein that promotes cancer cell growth and is used as a biomarker for heart failure, has been linked to tumors observed in two rare genetic diseases, according to a study published July 11, 2017, in eLife.
Matrixx Initiatives, Inc. and H.I.G. Capital, LLC, a leading global private investment firm, today announced that the subsequent offering period of the tender offer for all of the outstanding shares of common stock of Matrixx by Wonder Holdings, Inc. ("Wonder") and Wonder Holdings Acquisition Corp., both affiliates of H.I.G. formed for the purpose of acquiring Matrixx, for $8.75 per share in cash, without interest and less any applicable withholding taxes, expired at 11:59 p.m., New York City time, on Thursday, February 17, 2011.
› Verified 4 days ago
| NPI Number | 1568861490 |
| Organization Name | LAMAR ESTATES, LLC |
| Address | 205 S 10th St, Lamar, CO 81052 |
| Phone Number | 719-336-3434 |
News Archive
Researchers have developed cancer drug-packed 'grenades' armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
The World Health Organization (WHO), in consultation with the government of the United Kingdom, has designated the Liverpool School of Tropical Medicine (LSTM) as a WHO Collaborating Centre for Evidence Synthesis for Infectious and Tropical Diseases.
Galectin-3, a protein that promotes cancer cell growth and is used as a biomarker for heart failure, has been linked to tumors observed in two rare genetic diseases, according to a study published July 11, 2017, in eLife.
Matrixx Initiatives, Inc. and H.I.G. Capital, LLC, a leading global private investment firm, today announced that the subsequent offering period of the tender offer for all of the outstanding shares of common stock of Matrixx by Wonder Holdings, Inc. ("Wonder") and Wonder Holdings Acquisition Corp., both affiliates of H.I.G. formed for the purpose of acquiring Matrixx, for $8.75 per share in cash, without interest and less any applicable withholding taxes, expired at 11:59 p.m., New York City time, on Thursday, February 17, 2011.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Researchers have developed cancer drug-packed 'grenades' armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
The World Health Organization (WHO), in consultation with the government of the United Kingdom, has designated the Liverpool School of Tropical Medicine (LSTM) as a WHO Collaborating Centre for Evidence Synthesis for Infectious and Tropical Diseases.
Galectin-3, a protein that promotes cancer cell growth and is used as a biomarker for heart failure, has been linked to tumors observed in two rare genetic diseases, according to a study published July 11, 2017, in eLife.
Matrixx Initiatives, Inc. and H.I.G. Capital, LLC, a leading global private investment firm, today announced that the subsequent offering period of the tender offer for all of the outstanding shares of common stock of Matrixx by Wonder Holdings, Inc. ("Wonder") and Wonder Holdings Acquisition Corp., both affiliates of H.I.G. formed for the purpose of acquiring Matrixx, for $8.75 per share in cash, without interest and less any applicable withholding taxes, expired at 11:59 p.m., New York City time, on Thursday, February 17, 2011.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $50914 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 15.93 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.84 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 82.35 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 4.26 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 5.04 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 18.8 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.77 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.15 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 9.52 | 14.2 |